No need to login to view prices!
|Create new account|
Due to technical maintenance the webshop is closed until January 3rd, 2022. We wish you a successful 2022!
DANVERS, MA (PRWEB) -- April 12, 2016, Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, released four new monoclonal antibodies relevant to the rapidly growing fields of immunometabolism and tumor immunology.
CST has released Arginase-1 (D4E3M™) XP® #93668, LAG3 (D2G4O™) #15372, ICOS (D1K2T™) (IHC Specific) #89601, and PD-L1 (D5V3B) (Mouse Specific; IHC Specific) #64988 rabbit monoclonal antibodies (mAbs). These rabbit mAbs complement CST’s expanding portfolio of products that support tumor immunology research, including antibodies detecting the PD-1/PD-L1 family of immune checkpoint proteins, as well as metabolic targets, such as IDO, that have been proposed to promote immune suppression within the tumor microenvironment. Introduction of ICOS rabbit mAb also highlights the growing list of antibodies that detect co-stimulatory molecules, such as CD40L, OX40, and OX40L that research studies have demonstrated to have a role in augmenting anti-tumor immune responses.
All four newly released antibodies are recommended for immunohistochemistry (IHC), an application that helps visualize protein expression in the context of preserved tissue architecture, which is key to the translational research community interested in the study of tumor immunology.
Notably, the newly released Arginase-1 rabbit mAb exhibits mouse as well as human reactivity, while the new rabbit mAb targeting PD-L1 demonstrates exclusive specificity to mouse tissue, a critical feature to enable pre-clinical studies, typically carried out in murine models of disease.
CST’s recent announcement introducing the company’s capabilities to produce stringently characterized GMP-grade recombinant rabbit monoclonal antibodies further reinforces the impact that Arginase-1, LAG3, ICOS, PD-L1, and other related antibodies from CST could have on fostering the transition from basic to translational research.
“With the release of these antibodies, we are continuing to build on a rich repertoire of products that are highly enabling to the research community interested in tumor immunology. Our goal is to help scientists understand how tumors interact with the cells of the immune system and how ancillary immunosuppressive factors promote tumor growth. We hope that this understanding may help inform better treatment strategies for many cancers,” said Michael J. Comb, CEO of CST.